OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis
Shudi Li, Fei Duan, Suling Li, et al.
Annals of Hepatology (2023) Vol. 29, Iss. 2, pp. 101174-101174
Open Access | Times Cited: 15

Showing 15 citing articles:

Silymarin and Inflammation: Food for Thoughts
Peter F. Surai, Anton Surai, Katie Earle-Payne
Antioxidants (2024) Vol. 13, Iss. 1, pp. 98-98
Open Access | Times Cited: 18

Mitigating Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): The Role of Bioactive Phytoconstituents in Indian Culinary Spices
Pervej Alom Barbhuiya, Ameena Ahmed, Partha Dutta, et al.
Current Nutrition Reports (2025) Vol. 14, Iss. 1
Closed Access | Times Cited: 2

Consensus Guidelines for the Diagnosis and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Adult Asian Indians with Type 2 Diabetes
Anoop Misra, Ashish Kumar, Mohammad Shafi Kuchay, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2025) Vol. 19, Iss. 3, pp. 103209-103209
Closed Access | Times Cited: 2

Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches
Tatjana Radosavljević, Milica Branković, Janko Samardžić, et al.
Antioxidants (2024) Vol. 13, Iss. 8, pp. 906-906
Open Access | Times Cited: 15

A Comprehensive Review of Metabolic Dysfunction-Associated Steatotic Liver Disease: Its Mechanistic Development Focusing on Methylglyoxal and Counterbalancing Treatment Strategies
Izabela Berdowska, M. Matusiewicz, Izabela Fecka
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2394-2394
Open Access

Resmetirom: The First Disease‐Specific Treatment for MASH
Ali Mohamed Mousa, Mervat Mahmoud, Ghaida Mubarak AlShuraiaan
International Journal of Endocrinology (2025) Vol. 2025, Iss. 1
Open Access

Neoagarooligosaccharides improve non-alcoholic fatty liver disease by modulating lipid metabolism and Nrf2-related pathways
Subin Bae, Je Hyeon Lee, Su Jung Kim, et al.
Journal of Functional Foods (2025) Vol. 127, pp. 106737-106737
Closed Access

Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury
Kasra Shahsavari, Shireen Shams Ardekani, Mohammad Reza Shams Ardekani, et al.
BMC Complementary Medicine and Therapies (2025) Vol. 25, Iss. 1
Open Access

Combining nutraceuticals and a mediterranean diet for managing metabolic dysfunction associated with steatotic liver disease
Fong-Kuei Cheng, Cong Chen, Fei Wang, et al.
World Journal of Hepatology (2025) Vol. 17, Iss. 4
Closed Access

Nutraceutical Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Path to Liver Health
Emmanouil Vrentzos, George Pavlidis, Emmanouil Korakas, et al.
Nutrients (2025) Vol. 17, Iss. 10, pp. 1657-1657
Open Access

A patient-centered approach to dietary supplements for patients with chronic liver disease
Jennifer C. Lai, Melinda Ring, Anand Dhruva, et al.
Hepatology Communications (2024) Vol. 8, Iss. 11
Open Access | Times Cited: 1

The 2023 WCIRDC: Obesity
Zachary T. Bloomgarden
Journal of Diabetes (2024) Vol. 16, Iss. 4
Open Access

Page 1

Scroll to top